Tengfei Liu , Tingya Wang , Wenyan Yao , Xiangdong Lai , Lin Zou , Wenyu Sun , Liu Liu , Yihan Yuan , Chen Liu , Xiaohui Liu , Xuemei Wang , Hui Jiang
{"title":"膜融合和甘露糖靶向囊泡作为免疫增强型生物仿生纳米疫苗,用于黑色素瘤的预防和治疗","authors":"Tengfei Liu , Tingya Wang , Wenyan Yao , Xiangdong Lai , Lin Zou , Wenyu Sun , Liu Liu , Yihan Yuan , Chen Liu , Xiaohui Liu , Xuemei Wang , Hui Jiang","doi":"10.1016/j.nantod.2024.102333","DOIUrl":null,"url":null,"abstract":"<div><p>Melanoma is a tumor sensitive to immune response and its immunotherapy has been a research hotspot in recent years. By fusion of melanoma cell membranes and bacterial exosomes through sequential extrusion, we herein design a three-in-one multi-antigenic nanovaccine, namely TBM, to rapidly target immune system. TBM can induce RAW264.7 macrophage cells to differentiate into M1 type cells to release cytotoxic cytokines. It can also promote the maturation and antigen presentation of bone marrow-derived dendritic cells, thus activating spleen T cells to kill B16F10 melanoma cells <em>in vitro</em>. TBM can significantly inhibit the growth and metastasis of melanoma <em>in vivo</em>, and prolong the lifetime of mice, suggesting the preventive effects of vaccines. Further, we integrate cell membranes from mouse melanoma tissues into a novel personalized therapeutic vaccine, namely autologous TBM (ATBM). ATBM combined with Anti PD1 can activate anti-tumor immune response and increase the survival rate of melanoma allografted mice, as supported by eukaryotic reference mRNA-Seq transcriptome sequencing. Generally, this study demonstrates the preventive and therapeutic effects of biomimetic nanovaccines against melanoma, which may be extended to design personalized tumor vaccines for all tumors with immunogenicity, showing great clinical perspectives.</p></div>","PeriodicalId":395,"journal":{"name":"Nano Today","volume":null,"pages":null},"PeriodicalIF":13.2000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Membrane-fused and mannose-targeted vesicles as immunoenhanced biomimetic nanovaccines for prevention and therapeutics of melanoma\",\"authors\":\"Tengfei Liu , Tingya Wang , Wenyan Yao , Xiangdong Lai , Lin Zou , Wenyu Sun , Liu Liu , Yihan Yuan , Chen Liu , Xiaohui Liu , Xuemei Wang , Hui Jiang\",\"doi\":\"10.1016/j.nantod.2024.102333\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Melanoma is a tumor sensitive to immune response and its immunotherapy has been a research hotspot in recent years. By fusion of melanoma cell membranes and bacterial exosomes through sequential extrusion, we herein design a three-in-one multi-antigenic nanovaccine, namely TBM, to rapidly target immune system. TBM can induce RAW264.7 macrophage cells to differentiate into M1 type cells to release cytotoxic cytokines. It can also promote the maturation and antigen presentation of bone marrow-derived dendritic cells, thus activating spleen T cells to kill B16F10 melanoma cells <em>in vitro</em>. TBM can significantly inhibit the growth and metastasis of melanoma <em>in vivo</em>, and prolong the lifetime of mice, suggesting the preventive effects of vaccines. Further, we integrate cell membranes from mouse melanoma tissues into a novel personalized therapeutic vaccine, namely autologous TBM (ATBM). ATBM combined with Anti PD1 can activate anti-tumor immune response and increase the survival rate of melanoma allografted mice, as supported by eukaryotic reference mRNA-Seq transcriptome sequencing. Generally, this study demonstrates the preventive and therapeutic effects of biomimetic nanovaccines against melanoma, which may be extended to design personalized tumor vaccines for all tumors with immunogenicity, showing great clinical perspectives.</p></div>\",\"PeriodicalId\":395,\"journal\":{\"name\":\"Nano Today\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":13.2000,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nano Today\",\"FirstCategoryId\":\"88\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1748013224001889\",\"RegionNum\":1,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nano Today","FirstCategoryId":"88","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1748013224001889","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Membrane-fused and mannose-targeted vesicles as immunoenhanced biomimetic nanovaccines for prevention and therapeutics of melanoma
Melanoma is a tumor sensitive to immune response and its immunotherapy has been a research hotspot in recent years. By fusion of melanoma cell membranes and bacterial exosomes through sequential extrusion, we herein design a three-in-one multi-antigenic nanovaccine, namely TBM, to rapidly target immune system. TBM can induce RAW264.7 macrophage cells to differentiate into M1 type cells to release cytotoxic cytokines. It can also promote the maturation and antigen presentation of bone marrow-derived dendritic cells, thus activating spleen T cells to kill B16F10 melanoma cells in vitro. TBM can significantly inhibit the growth and metastasis of melanoma in vivo, and prolong the lifetime of mice, suggesting the preventive effects of vaccines. Further, we integrate cell membranes from mouse melanoma tissues into a novel personalized therapeutic vaccine, namely autologous TBM (ATBM). ATBM combined with Anti PD1 can activate anti-tumor immune response and increase the survival rate of melanoma allografted mice, as supported by eukaryotic reference mRNA-Seq transcriptome sequencing. Generally, this study demonstrates the preventive and therapeutic effects of biomimetic nanovaccines against melanoma, which may be extended to design personalized tumor vaccines for all tumors with immunogenicity, showing great clinical perspectives.
期刊介绍:
Nano Today is a journal dedicated to publishing influential and innovative work in the field of nanoscience and technology. It covers a wide range of subject areas including biomaterials, materials chemistry, materials science, chemistry, bioengineering, biochemistry, genetics and molecular biology, engineering, and nanotechnology. The journal considers articles that inform readers about the latest research, breakthroughs, and topical issues in these fields. It provides comprehensive coverage through a mixture of peer-reviewed articles, research news, and information on key developments. Nano Today is abstracted and indexed in Science Citation Index, Ei Compendex, Embase, Scopus, and INSPEC.